Lupin has received final approval for its Hydroxychloroquine Sulfate Tablets USP, 200 mg from the United States Food and Drug Administration (FDA) to market a generic version of Concordia Pharmaceuticals, Inc.'s Plaquenil Tablets, 200 mg.
Lupin's Hydroxychloroquine Sulfate Tablets USP, 200 mg is the generic version of Concordia Pharmaceuticals, Inc.'s Plaquenil Tablets, 200 mg. It is indicated for:
- the treatment of uncomplicated malaria due to P. falciparum, P. malariae, P. ovale, and P. vivax
- the prophylaxis of malaria in geographic areas where chloroquine resistance is not reported
- the treatment of chronic discoid lupus erythernatosus and systemic lupus erythematosus in adults
- the treatment of acute and chronic rheumatoid arthritis in adults
Hydroxychloroquine Sulfate Tablets USP, 200 mg had annual sales of approximately USD 215.3 million in the US (IQVIA MAT April 2018).
Shares of LUPIN LTD. was last trading in BSE at Rs.911.95 as compared to the previous close of Rs. 915.8. The total number of shares traded during the day was 114820 in over 2447 trades.
The stock hit an intraday high of Rs. 929.65 and intraday low of 909.4. The net turnover during the day was Rs. 105557262.